IP Library Granted Patent US 7,285,553
Granted Patent B2
US 7,285,553 · App. 11/265,030 · Granted Oct 23, 2007

Serotonergic 5HT

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,285,553
App. No.
11/265,030
Granted
Oct 23, 2007
Kind
B2
Abstract

Compounds with 5HT 7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.

Claims (14)

1. A compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached form a heterocyclic ring selected from the group consisting of piperazine, which is substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl;

R 11 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 12 is C 1-4 alkyl or a fused bicyclic heteroaromatic ring selected from the group consisting of thieno[3,2-e]-1,2-thiazine, and 1,2-benzothiazine, or R 12 can be joined to R 11 to form 1,3-dihydro-benzo[c]isothiazole;

n is 2 to 4

or a pharmaceutically acceptable salt thereof.

2. A topically administrable ophthalmic composition comprising a pharmaceutically effective amount of a compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached form a heterocyclic ring selected from the group consisting of piperazine, which is substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl,

R 11 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 12 is C 1-4 alkyl or a fused bicyclic heteroaromatic ring selected from the group consisting of thieno[3,2-e]-1,2-thiazine, and 1,2-benzothiazine, or R 12 can be joined to R 11 to form 1,3-dihydro-benzo[c]isothiazole;

n is 2 to 4

or a pharmaceutically acceptable salt thereof.